Bryan Blair

Garik Shmois

Susan Maklari

Timothy Wojs

Adam Baumgarten

David Macgregor

Keith Hughes

Saree Boroditsky

Joseph Nolan

Tomohiko Sano

- CSL Vifor and Travere Therapeutics support the recently published **KDIGO 2025 clinical practice guidelines for IgA Nephropathy (IgAN)**, which define diagnostic criteria, treatment goals, and treatment approaches for the disease.  **[790051_20250926PH83189:0]** 
- The updated guidelines suggest treatment with **FILSPARI® (sparsentan)**, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), as a potential first-line approach for IgAN-induced nephron loss, noting its proven efficacy compared to optimized RASi in clinical trials.  **[790051_20250926PH83189:0]** 
- The PROTECT Study, a Phase 3 trial, showed that FILSPARI achieved a **49.8% mean reduction in proteinuria from baseline** after 36 weeks, significantly outperforming the 15.1% reduction seen in irbesartan-treated patients.  **[790051_20250926PH83189:1]** 
- FILSPARI is a **non-immunosuppressive therapy** approved in the U.S. and Europe, and has been launched in Germany, Austria, Switzerland, Luxembourg, and the UK.  **[790051_20250926PH83189:0]** **[790051_20250926PH83189:2]**

CSL Vifor and Travere Therapeutics Acknowledge Updated KDIGO Guidelines for IgA Nephropathy

CARLISLE COMPANIES (CSL)